Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Common Stock · CUSIP: 05338F306

Event date: 2025-12-31

Filing-level shares
804,084
Percent of class
4.43%
  • The Vanguard Group

    Shares: 804,084 · Class: 4.43%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000102909-26-000048
Form type
SCHEDULE 13G/A
Filer
Avalo Therapeutics, Inc.
CIK
CIK 1534120
Filed
Jan 30, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub